Nektar Therapeutics logo

NKTR

Nektar Therapeutics

$4.66

Earnings Summary

Revenue
$24.82Mn
Net Profits
$-90.39Mn
Net Profit Margins
-364.16%

Highlights

Revenue:

Nektar Therapeutics’s revenue jumped 4.97% since last year same period to $24.82Mn in the Q1 2022. On a quarterly growth basis, Nektar Therapeutics has generated -0.75% fall in its revenue since last 3-months.

Net Profits:

Nektar Therapeutics’s net profit jumped 26.49% since last year same period to $-90.39Mn in the Q1 2022. On a quarterly growth basis, Nektar Therapeutics has generated 37.94% jump in its net profits since last 3-months.

Net Profit Margins:

Nektar Therapeutics’s net profit margin jumped 29.97% since last year same period to -364.16% in the Q1 2022. On a quarterly growth basis, Nektar Therapeutics has generated 37.47% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Nektar Therapeutics post its latest quarter earnings

EPS Estimate Current Quarter
-0.94
EPS Estimate Current Year
-0.94

Highlights

EPS Estimate Current Quarter:

Nektar Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.94 - a -38.24% fall from last quarter’s estimates.

EPS Estimate Current Year:

Nektar Therapeutics’s earning per share (EPS) estimates for the current year stand at -0.94.

Key Ratios

Key ratios of the Nektar Therapeutics post its Q1 2022 earnings

Earning Per Share (EPS)
-0.49
Return on Assets (ROA)
-0.22
Return on Equity (ROE)
-0.77
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Nektar Therapeutics’s earning per share (EPS) jumped 27.94% since last year same period to -0.49 in the Q1 2022. This indicates that the Nektar Therapeutics has generated 27.94% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Nektar Therapeutics’s return on assets (ROA) stands at -0.22.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Nektar Therapeutics’s return on equity (ROE) stands at -0.77.

Dividend Per Share (DPS):

Nektar Therapeutics declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-06
-0.68
-0.49
27.94%

Company Information

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

Organisation
Nektar Therapeutics
Headquarters
San Francisco, California, US
Employees
718
Industry
Health Technology
CEO
Howard Robin